ViCentra Expands Financing to $98 Million

ViCentra has announced the second close of its Series D financing round, adding $13 million and increasing its total funding to $98 million. The additional money came from ROM Utrecht Region and a consortium of Dutch investors—including Venturing Tech—as well as increased support from existing investor Innovation Industries.

The latest funding will enable ViCentra to scale manufacturing, deepen commercial execution in Germany, the Netherlands, and France, and accelerate preparations for its next-generation Kaleido insulin patch pump for U.S. market access. 

The second Series D financing round close follows the successful $85 million raised last fall and underscores investor confidence in ViCentra’s strategy, commercial traction, and operational performance, according to the company. With this strengthened financial backing, ViCentra is well-positioned to accelerate growth and build its leadership in the expanding insulin delivery market, executives claim.

ViCentra touts its flagship product, Kaleido, as the smallest, lightest, and most precise insulin patch pump in its class. Designed to feel like personal technology, it features customizable aluminum shells offered in 10 vibrant colors, allowing users to seamlessly blend medical innovation with their individual style.

“The past year has been transformative for ViCentra. This latest funding enables us to further scale our manufacturing capabilities, strengthen our commercial presence and support in Germany, the Netherlands, and France, and ensures that we remain on course for our planned U.S. market access. Our goal for 2026 is clear: convert our current high demand into satisfied users through quality and performance, and nearly triple our European user base by the end of 2026,” ViCentra CEO Tom Arnold said.

In 2025, ViCentra delivered considerable commercial and operational gains, doubling its user base to more than 4,000 and achieving strong associated revenue growth. This momentum, together with expanded manufacturing capacity and robust adoption in Germany—the world’s second-largest insulin pump market—as well as in the Netherlands and France, establishes a solid foundation for continued growth in 2026, company leaders contend.

ViCentra aims to improve life with diabetes through empathetic innovation, simplicity, and design excellence. The company develops and manufactures the Kaleido insulin patch pump system, a flexible, discreet alternative to traditional insulin pumps. Headquartered in Utrecht, the Netherlands, ViCentra is expanding across Europe and preparing for U.S. market entry. Its investors include Innovation Industries, Partners in Equity, Invest-NL, EQT Life Sciences, ROM Utrecht Region, Venturing Tech, Health Innovations and INKEF. 

Kaleido claims to be the first insulin patch pump designed with the form, function, and simplicity of a lifestyle product. Compact, featherlight, and discreet, Kaleido’s focus is on personal technology rather than a traditional medical device. It is made from premium materials and features customizable aluminum shells in 10 color options. In addition, it offers users flexibility in the way in which they wear their pump, allowing people with diabetes to manage their therapy in a way that fits seamlessly into their daily lives. ViCentra is marketing Kaleido as the smallest, lightest, most precise insulin patch pump in its class—delivering advanced, automated insulin therapy through seamless integration with Diabeloop’s clinically validated hybrid closed loop algorithms, DBLG1 and DBLG2.